Evaxion Biotech (EVAX) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Evaxion Biotech (EVAXResearch Report) today and set a price target of $18.00. The company’s shares closed last Thursday at $6.13.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 41.9% and a 47.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Taysha Gene Therapies.

Evaxion Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $18.20.

See today’s analyst top recommended stocks >>

Evaxion Biotech’s market cap is currently $130.6M and has a P/E ratio of -8.00. The company has a Price to Book ratio of 5.48.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market.